Post by FoundersToday

German biotech pioneer Tubulis GmbH, a leader in next-generation antibody-drug conjugate (ADC) therapeutics, has closed a €308 million ($361 million) Series C financing round, marking both the largest Series C in European biotech history and the largest private fundraising globally for an ADC company. The round was led by Venrock Healthcare Capital Partners, with participation from new investors Wellington Management and Ascenta Capital. Existing backers — including Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, Fund+, OCCIDENT, Seventure Partners, and HTGF | High-Tech Gründerfonds — also joined the round. 𝗥𝗘𝗔𝗗 𝗧𝗛𝗘 𝗗𝗘𝗧𝗔𝗜𝗟𝗦 👉 https://lnkd.in/dsXBq_zi Dr. Anil Jagtap Adriane Krahe Bjoern Hock Günter Fingerle-Rowson Stella Paffenholz, PhD Inês Vasconcelos Bettina Deisenrieder Christoph Broja John de Koning Mohammed Saleem Farooqi Norman Moullan, PhD, MBA Christian Groendahl Kanishka Pothula Jonas Helma-Smets Simon Vogt Marc-André Kasper Ingo Lehrke Katharina Heinzelmann Manuela Duerr Dr. Bernhard Seehaus Moetaz Albizem Annette Vogl Mary Ann Lumiqued Armin Weidmann Ella Jobson Matthew Norkunas, M.D. Rodney Callaghan Dominik Schumacher #Startups #Founders #FundingNews #VentureCapital #BioTech #SeriesC